Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.

207940

Rang in aandelen #498
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Aandeelprijs
$1,028.49
Marktkapitalisatie
$47.88B
Verandering (1 dag)
-3.67%
Verandering (1 jaar)
-18.37%
Land
KR
Handel Samsung Biologics Co.,Ltd. (207940)

Categorie

Healthcare
P/B-ratio voor Samsung Biologics Co.,Ltd. (207940)
P/B-ratio op October 2026 TTM: 7.59
Volgens de meest recente financiële rapporten en aandelenkoers van Samsung Biologics Co.,Ltd. is de huidige P/B-ratio (TTM) 7.59. Eind 2024 had het bedrijf een P/B-ratio van 6.19.
P/B-ratiohistoriek voor Samsung Biologics Co.,Ltd. van 2014 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) 7.59 -27.89%
2025 10.52 69.82%
2024 6.19 8.43%
2023 5.71 -11.02%
2022 6.42 -46.93%
2021 12.10 0.73%
2020 12.01 80.63%
2019 6.65 10.48%
2018 6.02 -8.12%
2017 6.55 197.83%
2016 2.20 -43.49%
2015 3.89 -78.44%
2014 18.05 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
6.6964 -11.72%
US
13.6307 79.69%
US
4.4521 -41.31%
AU
4.2241 -44.31%
BE
6.3632 -16.11%
NL